Alacrita stengthens Cambridge, MA team. Appoints William Slichenmyer as Associate Partner

ALACRITA STRENGTHENS CAMBRIDGE, MA TEAM TO ADVISE CLIENTS ON CLINICAL DEVELOPMENT STRATEGY, PLANNING AND OPERATIONS

Appoints William Slichenmyer as Associate Partner

Cambridge, MA, and London, UK, 7th January 2015 – Alacrita, the rapidly growing, transatlantic life sciences consulting firm, today announced that it has appointed William (Bill) Slichenmyer as an Associate Partner based in its Cambridge, MA office.

The move strengthens Alacrita’s Cambridge team and in particular consolidates its position as a leading provider of expert advice to life science companies looking to develop and launch novel therapeutic agents.  For over 20 years Bill has held leadership and executive roles in large and small pharma companies including AVEO Oncology, Pfizer, Parke-Davis, Bristol-Myers Squibb, Merrimack Pharmaceuticals and Hybridon.  His responsibilities in these roles have spanned across clinical development, medical affairs and regulatory affairs, from preclinical development through post-marketing trials.  Bill earned his MD degree at Case Western Reserve University.  He received specialty training in internal medicine at the University of Texas Health Science Center in San Antonio and medical oncology at the Johns Hopkins Oncology Center.  He earned the ScM degree in Clinical Investigation at the Johns Hopkins University.

Bill joins a growing team of specialists at Alacrita who have distinguished track records of starting and growing life science businesses. Alacrita is supported by a team of Associates across Europe and the U.S., all of whom are carefully selected for their deep life science industry experience and expertise. The firm supports clients with life science strategy, due diligence and operational support.

Bill Slichenmyer said “I am delighted to be joining the Alacrita team, which has an impressive track record of advising client organizations in the life sciences.  The pace of innovation in our industry is accelerating while the regulatory and payer environments are evolving rapidly.  I look forward to engaging with our clients on their drug development and commercialization efforts.”

Rob Johnson, Partner at Alacrita, said: “We are delighted to welcome Bill to Alacrita as we build a best-in-class consulting practice to help companies with strategy, planning and operational support. Bill is an experienced executive and his expertise is rooted in reality, having first-hand experience of developing numerous anticancer drugs. He has deep and broad knowledge of the pharmaceutical industry and a sound understanding of the challenges faced by senior management. He joins a high calibre team of seasoned consultants and underlines our commitment to providing exceptionally high quality advice to the industry.”

Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

Stay in touch